Advantages of using semaglutide in the treatment of obesity and overweight - A literature review
DOI:
https://doi.org/10.33448/rsd-v13i11.47456Keywords:
Semaglutide; Lifestyle; Obesity.Abstract
Obesity is a multifactorial condition associated with health risks, requiring effective and safe therapeutic approaches for weight control. The objective of the present study is to present a review of scientific evidence on the advantages of semaglutide in the treatment of obesity, to raise awareness among readers, and to expand knowledge on the topic. An integrative literature review was conducted using Google Scholar, MEDLINE/PUBMED, and SciELO, considering articles published between 2014 and 2024. Studies on the efficacy, safety, and role of healthcare professionals in the use of semaglutide for obese or overweight patients were included. Semaglutide, a GLP-1 receptor agonist, demonstrated an average body weight reduction of 10% to 15% across multiple studies, acting by decreasing appetite and increasing satiety. Patients treated with semaglutide showed better long-term weight control when compared to non-pharmacological interventions alone. Semaglutide proved to be an effective and safe pharmacological option for weight loss, especially for patients struggling with weight management through lifestyle changes alone. However, the treatment requires continuous monitoring and behavioral changes to maintain results. Additional studies are recommended to explore its efficacy in different population subgroups and assess long-term effects.
References
ABESO - Associação Brasileira para Estudo da Obesidade e Síndrome Metabólica. (2016). Diretrizes Brasileiras de Obesidade 2016 (4ª ed.). VI Diretrizes Bras. Obesidade, 7–186.
Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., Fatima, H., & Nwankwo, I. (2022). Efficacy of semaglutide in treating obesity: A systematic review of randomized controlled trials (RCTs). Cureus, 14(12), e32610. doi: 10.7759/cureus.32610
Arlota, F. B., Garcia, L. B. L., Costa, A. C. C., Santos, E. S. D., Alvim, D. C., Ribeiro, P. L. L., Neves, Y. H. M., Freitas, A. C. G., Farage, M. R., & Rangel, L. O. R. (2024). Efeitos da Semaglutida na perda de gordura e de massa muscular. Brazilian Journal of Implantology and Health Sciences, 6(2), 2018-2035.
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., & PIONEER 1 Investigators. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 42(9), 1724-1732. doi: 10.2337/dc19-0749
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2022). Semaglutide for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism, 25(1), 18-35. Wiley. http://dx.doi.org/10.1111/dom.14863
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251. doi: 10.1111/dom.12932
Brasil. (2016). Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica: Diretrizes brasileiras de obesidade (4ª ed.). VI Diretrizes Brasileiras de Obesidade.
Castro, J., Oliveira, J. M., Estrela, G., Cid, A., & Quirin, A. (2022). Epimeletic behavior in bottlenose dolphins (Tursiops truncatus) in the south of Portugal: Underwater and aerial perspectives. Aquatic Mammals, 48(6), 646-651.
Conte, S. C. (2014). Perspectivas de perda de peso com o uso de liraglutida: revisão da literatura. Brazilian Journal of Surgery & Clinical Research, 9 (1). em https://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=23174404&AN=101978558&h=0QNJLdizCIKuxR%2BhMTOopPp06eVvetFLpHuL4SyFUZVE8HpdIgJAri9plCynMe5lmdxtJun8%2B1RZHHmNfAc8Lg%3D%3D&crl=c
Costa, A. C. C., Santos, E. S. dos, Alvim, D. C., Ribeiro, P. L. L., Neves, Y. H. M., Freitas, A. C. G. de, Arlota, F. B., Farage, M. R., Rangel, L. de O., Garcia, L. B. L., Pilon, J. K., & Camargo, T. R. (2024). Efeitos da semaglutida na perda de gordura e de massa muscular. Brazilian Journal of Implantology and Health Sciences, 6 (2), 2018-2035. doi: 10.36557/2674-8169.2024v6n2p2018-2035. https://bjihs.emnuvens.com.br/bjihs/article/view/1537
Crossetti, MGO. Revisão integrativa de pesquisa na enfermagem o rigor cientifico que lhe é exigido [editorial]. Rev Gaúcha Enferm., Porto Alegre (RS) 2012 jun;33(2):8-9.
Davies, M. J., et al. (2015). Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA, 314(7), 687-99.
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 23(3), 754-62. Doi: 10.1111/dom.14280
Geloneze, F. R., & Arielo, F. S. (2018). Um breve análise sobre a Indústria de Jogos Eletrônicos e os Indie Games. Revista Multiplicidade, 8(8). https://doi.org/10.59237/multipli.v8i8.102
GomesH. K. B. C., & TrevisanM. (2021). O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos. Com, 29, e7498. Recuperado de https://acervomais.com.br/index.php/artigos/article/view/7498
Gomes, H. K. B. C., & Trevisan, M. (2021). O uso do Ozempic (Semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos.Com, 29(1), e7498-e7498.
Gomes et al., 2021. Effect of environmental filters on Chironomidae (Insecta: Diptera) assemblages of neotropical watersheds. Limnetica 40-1, 2021: 19-31
Kushner, R. F., et al. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring), 28(6), 1050-1061.
Mohammed, M. S., et al. (2018). Systems and WBANs for Controlling Obesity. Journal of Healthcare Engineering. 1:2018:1564748.
doi: 10.1155/2018/1564748. eCollection 2018.
Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., Stemmer, K., Tang Christensen, M., Woods, S. C., DiMarchi, R. D., & Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130.
Pereira Cancino, Guillermo & Suz, Laura & Albornoz, Veronica & Romero, Christian & Garcia, Leonardo & Leiva, Victoria & Atala, Cristian & García-Rodríguez, José. (2018). Pereira et al 2018. 75. 447.
Phillips, A., & Clements, J. N. (2022). Clinical review of subcutaneous semaglutide for obesity. Journal of Clinical Pharmacy and Therapeutics, 47(2), 184-93. Doi: 10.1111/jcpt.13574
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. doi: 10.1001/jama.2021.3224
Silva, N. S., & De Mendonça, E. G. (2024). Uso racional da semaglutida na perda de peso (farmácia). Repositório Institucional, 2(2). https://revistas.icesp.br/index.php/Real/article/view/5095.
Simonson, M., Boirie, Y., & Guillet, C. (2020). Protein, amino acids and obesity treatment. Reviews in Endocrine and Metabolic Disorders, 21(3), 341-53.
Tan, H. C., Dampil, O. A., & Marquez, M. M. (2022). Efficacy and safety of semaglutide for weight loss in obesity without diabetes: A systematic review and meta-analysis. Journal of the ASEAN Federation of Endocrine Societies, 3 (2), 65-72. Doi: 10.15605/jafes.037.02.14
The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-64. Doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S.; STEP TEENS Investigators. (2022). Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine, 387(24), 2245-57. Doi: 10.1056/NEJMoa2208601
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384 (11), 989-1002. Doi: 10.1056/NEJMoa2032183
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide:
Yonemoto, N., et al. (2017). Efeitos do excesso de peso e da obesidade na saúde em 195 países com mais de 25 anos. New England Journal of Medicine, 377 (1), 13-27.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Emanuelle Luisa Fiorese; José Roberto Alves Filho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
